Growing Demand for Improved Drug Testing and Labeling
At ObesityWeek 2025, recent findings reveal strong public backing for thorough assessments and labeling of medications specifically for individuals with obesity.
New research unveiled at ObesityWeek, a leading conference focused on obesity science, highlights a significant expectation from those living with obesity towards the U.S. Food and Drug Administration (FDA) and pharmaceutical companies to bridge critical gaps in drug testing and labeling protocols.
Despite over 40% of U.S. adults being affected by obesity, the majority of medications do not undergo necessary pharmacokinetic testing in this demographic before being approved. This lack of scrutiny often leads to insufficient prescribing information, which is crucial for healthcare professionals aiming to provide accurate and effective treatment for this large and increasingly prominent population. When subsequent studies reveal changes in how drugs are metabolized or distributed among individuals with obesity, labeling updates are frequently neglected by manufacturers.
In a national survey conducted by top academic and advocacy organizations, the responses from individuals with obesity were enlightening once they were made aware of these shortfalls:
Public Reactions to Drug Testing Omissions
- 67% were unaware that many medications are not evaluated in individuals with obesity.
- 88% expressed anger regarding this oversight in the drug approval process.
- 86% believe that the FDA should mandate obesity-specific testing prior to drug approvals.
- 99% agreed that drug manufacturers must revise labels when obesity affects drug responses.
"This is a direct and consistent message from those deeply impacted by these gaps in drug safety," stated Fatima Cody Stanford, MD, MPH, MPA, MBA, a lead author of the study. "Patients with obesity are sounding the alarm for equitable protections in drug safety and effectiveness across the board."
Highlighting the Importance of Comprehensive Testing
The study specifically highlights posaconazole, an antifungal drug from Merck, which was approved without adequate testing in individuals with obesity. Recent data indicate that the medication's half-life is notably extended in this population, a crucial factor in determining proper dosage. However, the company has not made the necessary updates to its labeling.
After learning about this specific example, survey participants reacted as follows:
- 74% admitted they were previously unaware of this significant pharmacokinetic difference.
- 73% strongly preferred that this information should be included on the label.
- 73% firmly stated that the FDA should compel Merck to address this issue.
"This isn't just a concern for a minor segment of the population—it's a pressing public health challenge," noted Ted Kyle, RPh, MBA, co-author of the study. "With 40% of adults living with obesity, their unique physiological needs must be considered in research that informs clinical pHractices. The public expects accountability and better outcomes."
Details of the Survey Conducted
This national survey targeting individuals with obesity took place online in May 2025. The results are being showcased as a scientific poster at ObesityWeek 2025, which spans November 4 to November 7.
Key Contributors to the Research:
Clara E. Tandar, BS; John C. Lin, BS; Gwyn Cready, MBA; James Zervios, BA; Lisa Gresco-White; Michelle Vicari; Ted Kyle, RPh, MBA; and Fatima C. Stanford, MD, MPH, MPA, MBA.
About the Obesity Action Coalition (OAC): The OAC is a prominent national nonprofit organization that serves over 85,000 members, committed to empowering individuals affected by obesity through education, advocacy, and support.
Frequently Asked Questions
What is the main issue highlighted in the study?
The study emphasizes the need for improved drug testing and accurate labeling for medications used by individuals with obesity.
How did the public respond to drug testing for obesity?
Many individuals were unaware of the lack of testing in obesity, and a large percentage expressed anger and called for changes.
What specific drug is mentioned in the study?
The study specifically discusses posaconazole, an antifungal medication, and its lack of comprehensive testing for individuals with obesity.
What is the role of the Obesity Action Coalition?
The OAC advocates for people affected by obesity, providing education, awareness, and support for their needs.
Why is pharmacokinetic testing for obesity patients important?
Such testing ensures that medications are safe and effective, taking into account how they work differently in individuals with obesity.
